Spravato Operations Series
The Spravato Prior Authorization Playbook
Initial authorization, reauthorization windows, the documentation payers actually want, and the auth-expiry failure mode that quietly costs Spravato programs more than any denial.
Prior Authorization Is Not a One-Time Event
Most clinics treat the Spravato prior authorization as a gate you pass through once, at intake. That mental model is wrong, and it is the root of most Spravato revenue loss. A Spravato authorization is a live object with a start date, an end date, a session count, and a renewal cycle — and the patient’s treatment usually outlives it. The labeled dosing schedule alone tells you why: twice-weekly sessions in weeks 1–4, weekly in weeks 5–8, then every one to two weeks in maintenance, potentially for a year or more. Very few payers authorize that entire arc up front.
Run the authorization as a lifecycle — initial approval, tracked utilization, reauthorization on a deadline — and the program stays funded. Run it as a checkbox and you will eventually treat patients on dead auths.
The Initial Authorization: What Payers Want to See
Criteria vary by payer, but commercial PA requirements for treatment-resistant depression cluster around a predictable documentation set:
- Diagnosis and severity: A documented MDD diagnosis with current severity, usually supported by a standardized instrument — PHQ-9 is the most commonly requested; some payers accept or prefer MADRS or HAM-D scores.
- Failed-trial history: Documentation that the patient has failed at least two adequate trials of oral antidepressants in the current episode — drug names, doses, durations, and outcomes. Vague “tried several medications” notes get pended. Specific drug/dose/duration tables get approved.
- Treatment plan: The intended dosing schedule (induction cadence and target dose), the REMS-certified setting where treatment will occur, and — depending on indication and payer policy — whether esketamine is adjunctive to an oral antidepressant or, under the January 2025 FDA approval, used as monotherapy.
- Prescriber and site details: Some payers verify REMS certification status, site of care, and the prescriber’s network status before approving. A credentialing gap can stall a clinically clean PA — see credentialing services.
Build a PA packet template once, per payer, and reuse it. The clinics that win fast approvals are not writing better prose — they are answering the payer’s checklist in the payer’s order.
Reauthorization: The Window That Actually Matters
Initial approvals are commonly time-boxed (often one to six months, payer-dependent) or session-boxed (a set number of administrations), or both. Reauthorization typically asks a different question than the initial PA: not “does this patient qualify?” but “is this working?” Expect to document:
- Response evidence: Serial symptom scores — the same PHQ-9 (or equivalent) trail you started at baseline. If your workflow doesn’t capture scores at a regular cadence, reauthorization is where that gap becomes a payment problem.
- Utilization consistency: Sessions delivered roughly on protocol. Long unexplained gaps invite “is continued treatment medically necessary?” pushback.
- Continued-need rationale: Why maintenance continues — response maintained, relapse risk, taper plan where relevant.
Operationally, the rule we run: start the reauthorization when roughly 30 days or 4 sessions of runway remain, whichever comes first. Payer turnaround is unpredictable; the buffer is the point.
The Auth-Expiry Failure Mode
Here is how the most common Spravato revenue failure actually happens. A patient stabilizes into every-other-week maintenance. Treatment is routine; everyone relaxes. The authorization that covered induction quietly ends — a date passes, or session 24 of 24 gets used — and nothing in the clinic’s workflow surfaces it, because the schedule keeps generating appointments either way. The clinic delivers three, four, six more sessions. Then the denials arrive, weeks later, all at once: services not authorized. Retro-authorization sometimes works and often does not, and each unpaid session carries real drug cost, not just staff time.
Nobody made a clinical mistake. The failure is structural: appointment scheduling and authorization status live in different systems, and nothing joins them. That join — every scheduled session checked against a live auth with sessions remaining — is the control that fixes it. We cover the tracking mechanics in Spravato authorization tracking, and the tooling we build for it on the custom software page.
Payer Variation Patterns
Commercial Payers
Almost universally require PA, usually with the TRD documentation set above. Watch the benefit split: some plans cover the drug under the medical benefit (buy-and-bill), others push it through the pharmacy benefit via a REMS-certified specialty pharmacy — and the PA may live on that side. In our Oregon program we track distinct auth behaviors across Anthem, Providence, and UnitedHealthcare; assume every payer is its own playbook until proven otherwise.
Medicare
Traditional Medicare generally does not run a commercial-style PA gate, but coverage is governed by MAC billing articles and documentation requirements — and Medicare pays through bundled G-codes (G2082/G2083) rather than separate drug claims. Medicare Advantage plans, by contrast, usually do require prior authorization and behave more like commercial payers. Never assume “Medicare” means “no auth” without checking which Medicare.
Medicaid and CCOs
State Medicaid programs and managed plans (in Oregon, CCOs) vary the most: PA criteria, preferred acquisition pathway, and covered settings differ by state and by plan. Some require the specialty-pharmacy pathway outright. Verify plan-specific policy in writing before the first induction — Medicaid retro-auth is the least forgiving of the three lanes.
Everything above describes common patterns, not guarantees — payer policies change and individual plan documents control. The coding side of these differences is covered in our Spravato billing guide.
Tired of Finding Out About Expired Auths From the Denial Queue?
We run authorization lifecycles for interventional psychiatry programs — initial packets, reauth deadlines, and the tracking that keeps sessions funded.
Common Questions
How long does a Spravato prior authorization take?
Commonly a few business days to two weeks for commercial payers when the packet is complete; longer when documentation is missing or the request pends for clinical review. Incomplete failed-trial documentation is the most frequent cause of delay.
How many antidepressant failures do payers require for Spravato?
Most payers mirror the treatment-resistant depression definition: at least two adequate trials of oral antidepressants in the current episode, documented with drug, dose, duration, and outcome. Some payers add step requirements or augmentation-trial expectations — check the specific policy.
When should we start a Spravato reauthorization?
Our operating rule is to start when roughly 30 days or 4 sessions of authorization runway remain, whichever comes first. Payer turnaround varies too much to cut it closer, and a lapsed auth mid-maintenance means unpaid sessions with real drug cost attached.
Does Medicare require prior authorization for Spravato?
Traditional Medicare generally does not use a commercial-style PA process, though MAC billing-article and documentation requirements still apply. Medicare Advantage plans usually do require prior authorization. Always confirm which type of Medicare coverage the patient has.
Can we get paid retroactively if an authorization lapsed?
Sometimes — some payers allow retro-authorization or appeal with good-cause documentation, but many do not, and approval is never assured. Treat retro-auth as damage control, not a workflow. Prevention through tracking is dramatically cheaper.
What symptom scales should we use for Spravato documentation?
PHQ-9 is the most commonly requested by payers; MADRS and HAM-D also appear in policies. Whichever you use, capture it at baseline and on a regular cadence — reauthorization approvals lean heavily on a visible score trail.